Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhaled Medications01:23

Inhaled Medications

912
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
912
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.2K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.2K
Oral Drug Delivery Systems: Introduction01:23

Oral Drug Delivery Systems: Introduction

90
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
90
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

71
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
71
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

103
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
103
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices01:28

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

62
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
62

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global pMDI Use and the Potential Impact of European PFAS Legislation on Access to These Essential Inhaled Medications.

Pulmonary therapy·2026
Same author

Response.

Chest·2026
Same author

Exhaled breath condensate based breath analyser: Real-time thermofluidic standardisation of hydrogen peroxide for longitudinal COPD monitoring: a pilot investigation.

Respiratory medicine·2026
Same author

Small Airways Disease Adversely Impacts the Response to Biologic Therapies in Severe Asthma.

Pulmonary therapy·2026
Same author

A Challenging Diagnosis of Hemophagocytic Lymphohistiocytosis with Unusual Pulmonary Manifestations: A Case Report.

The open respiratory medicine journal·2026
Same author

Carbon dioxide equivalent emissions and cost impact of non-clinically driven inhaler initiation or switch for COPD.

Current medical research and opinion·2026

Related Experiment Video

Updated: Mar 2, 2026

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

1.5K

Recent advances in capsule-based dry powder inhaler technology.

Federico Lavorini1, Massimo Pistolesi1, Omar S Usmani2

  • 1Department of Experimental and Clinical Medicine, Careggi University Hospital, Largo Brambilla 3, 50134 Florence, Italy.

Multidisciplinary Respiratory Medicine
|May 25, 2017
PubMed
Summary

Dry powder inhalers (DPIs) offer direct lung drug delivery but face challenges due to complex device-patient interactions. Advances in capsule-based DPIs and disposable devices aim to improve therapeutic efficacy by reducing variability.

Keywords:
AsthmaChronic obstructive pulmonary diseaseDrug deliveryDry powder inhalersTechnology assessment

More Related Videos

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

8.1K
Intratracheal Administration of Dry Powder Formulation in Mice
07:55

Intratracheal Administration of Dry Powder Formulation in Mice

Published on: July 25, 2020

12.4K

Related Experiment Videos

Last Updated: Mar 2, 2026

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

1.5K
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

8.1K
Intratracheal Administration of Dry Powder Formulation in Mice
07:55

Intratracheal Administration of Dry Powder Formulation in Mice

Published on: July 25, 2020

12.4K

Area of Science:

  • Pulmonary drug delivery
  • Respiratory medicine
  • Biomedical engineering

Background:

  • Pulmonary drug delivery targets lung pathologies directly for maximum therapeutic benefit.
  • Dry powder inhalers (DPIs) are preferred for treating diverse lung diseases.
  • DPI performance relies on complex device-patient interactions, posing engineering challenges.

Purpose of the Study:

  • To review recent advances in capsule-based dry powder inhaler (DPI) technology.
  • To discuss the introduction and potential of disposable DPI devices.
  • To highlight strategies for improving drug delivery to deeper lung airways.

Main Methods:

  • Review of current literature on dry powder inhaler (DPI) technologies.
  • Analysis of engineering development challenges in DPI systems.
  • Examination of factors influencing aerosol performance and drug deposition.

Main Results:

  • Development of DPI systems involves optimizing drug formulations and delivery devices.
  • No single DPI device currently demonstrates superior clinical efficacy.
  • Significant inter- and intra-patient variability in lung drug dosage is a major clinical concern.

Conclusions:

  • Advances in capsule-based DPIs and disposable devices show promise for improved pulmonary drug delivery.
  • Addressing variability in drug delivery is crucial for enhancing pharmacological efficacy.
  • Continued innovation in DPI technology is needed to overcome current clinical limitations.